<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503477</url>
  </required_header>
  <id_info>
    <org_study_id>D8480C00023</org_study_id>
    <nct_id>NCT00503477</nct_id>
  </id_info>
  <brief_title>A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan</brief_title>
  <official_title>A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 Following Single and Multiple Oral Doses in Patients in Japan With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I open label dose escalation study to assess the safety and tolerability of AZD2171
      following single and multiple oral doses in patients in Japan with advanced solid
      malignancies. In addition there will be an expanded cohort multi-centre study phase with
      NSCLC patient and CRC patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Assessed at each visit for 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy, PK</measure>
    <time_frame>Assessed at each visit for 4 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">40</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2171</intervention_name>
    <description>oral tablet</description>
    <other_name>cediranib</other_name>
    <other_name>RECENTINâ„¢</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  advanced solid tumors

          -  life expectancy is 12 weeks or longer

        Exclusion Criteria:

          -  patient with uncontrolled brain metastases

          -  patient with inappropriate laboratory test values

          -  patient with poorly controlled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Robertson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tomohide Tamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre Hospital, Tokyo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2007</study_first_submitted>
  <study_first_submitted_qc>July 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2007</study_first_posted>
  <last_update_submitted>June 11, 2009</last_update_submitted>
  <last_update_submitted_qc>June 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jane Robertson, Medical Science Director,</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Japan</keyword>
  <keyword>Phase I</keyword>
  <keyword>solid tumor</keyword>
  <keyword>AZD2171</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cediranib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

